Treatment of Canine MRSP Skin Infections
For dogs with MRSP skin infections, aggressive topical therapy with 4% chlorhexidine (shampoo twice weekly plus solution daily) should be the first-line treatment for superficial pyoderma, reserving systemic antibiotics for severe, deep, or refractory cases.
Treatment Algorithm
Step 1: Assess Disease Severity
Superficial pyoderma (most common):
- Limited lesions without systemic signs
- No deep tissue involvement
- Start with topical therapy alone 1
Deep pyoderma or complicated infections requiring systemic therapy:
- Multiple sites of infection
- Rapid progression with cellulitis
- Systemic illness signs
- Immunosuppression or comorbidities
- Failed topical therapy
- Difficult-to-treat locations (face, genitalia)
Step 2: Topical Therapy (First-Line for Superficial Disease)
Chlorhexidine protocol 1:
- 4% chlorhexidine digluconate shampoo: twice weekly
- 4% chlorhexidine digluconate solution: once daily
- Duration: 4 weeks minimum
- This approach achieved complete resolution in all dogs with MRSP superficial pyoderma, including those with resistant strains 1
Alternative emerging option:
- Bacteriophage therapy (topical S. pseudintermedius phage once daily for 30 days) has shown success 2, though availability is limited
Step 3: Systemic Antibiotics (When Required)
When topical therapy alone is insufficient, select based on culture and susceptibility testing:
Rifampicin monotherapy 3:
- Dose: 6 mg/kg orally once daily for 21 days
- Efficacy: 82.7% clinical success rate
- Critical caveat: Rapid resistance develops in ≥10% of cases 3
- Avoid concurrent use with ciclosporin or fluconazole (increased severe adverse effects) 3
- Well-tolerated: 78.8% had no adverse effects 3
Other systemic options based on susceptibility 4, 5:
- Chloramphenicol
- Minocycline/doxycycline
- Clindamycin (if susceptible and local resistance <10%)
- Amikacin (for severe cases)
Duration: 7-14 days for complicated infections, individualized based on clinical response
Step 4: Adjunctive Measures
N-acetylcysteine (NAC) shows promise 6:
- Bactericidal at 12.8-25.6 mg/mL
- Synergistic with cephalexin against MRSP
- Kills bacteria within 120 seconds at MBC concentrations
- May be useful as topical adjunct, though clinical protocols need development
Critical Pitfalls to Avoid
Do not use rifampicin as monotherapy without considering resistance risk - 10.6% of dogs developed rapid resistance 3
Never combine rifampicin with ciclosporin or fluconazole - significantly increases severe adverse reactions 3
Avoid β-lactams entirely - MRSP is by definition resistant to all cephalosporins, penicillins, and amoxicillin-clavulanate 4, 5
Do not assume multidrug resistance means topical therapy won't work - chlorhexidine was equally effective regardless of resistance pattern 1
Reserve vancomycin and linezolid for human use only - ethical considerations and antimicrobial stewardship principles prohibit veterinary use 5
Infection Control
Implement environmental measures to prevent recurrence and spread:
- Clean high-touch surfaces regularly
- Keep wounds covered with clean, dry bandages
- Regular bathing with antiseptic products
- Hand hygiene for handlers
Evidence Quality Note
The provided guidelines 7 address human MRSA infections, not canine MRSP. While the organisms share methicillin resistance mechanisms, S. pseudintermedius is a distinct species requiring veterinary-specific treatment approaches. The veterinary research evidence 3, 1, 5 provides the most relevant guidance for canine MRSP and demonstrates that topical antiseptics can be as effective as systemic antibiotics for superficial disease, supporting antimicrobial stewardship principles.